Dr. Drilon on Emerging Biomarkers in NSCLC

Video

In Partnership With:

Alexander Drilon, MD, medical oncologist, clinical director, Early Drug Development Service, Memorial Sloan Kettering Cancer Center, discusses emerging biomarkers in non–small cell lung cancer (NSCLC).

Alexander Drilon, MD, medical oncologist, clinical director, Early Drug Development Service, Memorial Sloan Kettering Cancer Center, discusses emerging biomarkers in non—small cell lung cancer (NSCLC).

Aside from EGFR, ALK, and ROS1 mutations, there are several emerging biomarkers in NSCLC. The first group are the MET exon 14 alterations, which are found in approximately 4% of patients with NSCLC, says Drilon; these mutations result in activation of the MET pathway, and can be paired with certain targeted therapies. Several MET inhibitors were in development when exon 14 alterations were identified in clinical samples, he adds. Now, clinicians have data on crizotinib (Xalkori), capmatinib, and tepotinib. Capmatinib and tepotinib are selective inhibitors, whereas crizotinib is a multikinase inhibitor. Overall, the inhibitors show response rates around 30%.

In May 2018, crizotinib received a breakthrough therapy designation from the FDA for the treatment of patients with metastatic NSCLC with MET exon 14 alterations following progression on platinum-based chemotherapy. Moreover, a recent report showed that capmatinib induced a response rate above 70% in TKI-naïve patients.

Related Videos
Samilia Obeng-Gyasi, MD, MPH
Tycel Phillips, MD
Ajai Chari, MD
Reshma Jagsi, MD, DPhil, Emory University
Nisha A. Mohindra, MD, Northwestern University Feinberg School of Medicine
Katrina S. Pedersen, MD, MS, associate professor, John T. Milliken Department of Medicine, Division of Oncology, Medical Oncology program leader, cofounder, Young Onset Colorectal Cancer Program, Washington University School of Medicine in St. Louis, Siteman Cancer Center
Dan S. Childs, MD, medical oncologist, Mayo Clinic
Martin H. Voss, MD, an expert on renal cell carcinoma
Laurence Albigès, MD, PhD, an expert on renal cell carcinoma
A panel of 4 experts on hematologic malignancies